Atossa Genetics, now commonly referred to as Atossa Therapeutics (NASDAQ:ATOS), is a biopharmaceutical company focused on developing innovative medicines in the areas of breast cancer and other breast disorders. With a strong commitment to improving women's health, Atossa Therapeutics is dedicated to advancing its pipeline projects, which include proprietary therapeutics and novel methodologies for better drug delivery. The company prioritizes the research and development of solutions that can potentially transform the treatment landscape for patients battling breast cancer, aiming for more targeted and effective therapies. Operating out of its base in the United States, Atossa Therapeutics strives to meet the urgent needs of patients worldwide, aligning its objectives towards breakthroughs that offer hope and improved outcomes in breast health.